SEC Tracker
Get the app
TMDX · XBRL financial data

TransMedics Group financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TMDX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue6681*97114109122*144157144161*174190
Cost of revenue2633*37454850*55615967*7377
Gross profit4148*60696172*88978593*101113
Research and development1111*11141416*17161521*2532
Selling, general and administrative3135*36434347*44444651*6358
Total operating expenses6945*48575763*61606172*8889
Operating income (loss)(28)3*121349*27372321*1324
Interest expense44*4444*3333*77
Other income (expense)55*——————————
Income tax expense (benefit)—year only0(0)00*11(1)(84)*15
Net income (loss)(25)4*121247*263524105*715
Earnings per share, basic USD per share(0.78)0.12*0.370.370.130.20*0.761.030.713.08*0.210.42
Earnings per share, diluted USD per share(0.78)0.12*0.350.350.120.19*0.700.920.662.57*0.200.41
Weighted average shares, basic millions of shares3333*33333334*34343434*3435
Weighted average shares, diluted millions of shares3333*35353635*40414141*3641

Balance sheet

CSV

Fiscal quarters (TMDX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents427395350363330337311401467489480491
Accounts receivable616482819098142105818491104
Inventory394449495247433945495054
Prepaid and other current assets1088172016101422161720
Total current assets537511488509492497506558613638619651
Property and equipment, net131174214229272286311312313328362365
Right-of-use asset776676666555
Goodwill121212121212121212121212
Total assets6897067247597868048388919461,0681,4351,464
Accounts payable13139131310111012101113
Current portion of long-term debt————————5101520
Total current liabilities495550546060565780899298
Lease liability, non-current887776654432
Total liabilities563569564569576575571572591595941946
Accumulated deficit(508)(504)(492)(479)(475)(468)(443)(408)(383)(278)(271)(256)
Total stockholders' equity126137159190210229266318355473494518
Total liabilities and equity6897067247597868048388919461,0681,4351,464
Common shares outstanding (cover page) millions of shares333333333434343434343535

Cash flows

CSV

Fiscal quarters (TMDX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(25)4*121247*263524105*715
Stock-based compensation5*6*78*8*11*99*9*9*109*
Depreciation and amortization2*4*45*5*6*67*7*7*1210*
Net cash from operating activities(7)*8*(3)26*7*20*(3)92*70*35*2517*
Purchases of property and equipment108*42*4424*48*14*279*8*16*377*
Net cash from investing activities(150)*(42)*(44)(24)*(48)*(14)*(27)(9)*(8)*(16)*(37)(7)*
Net cash from financing activities2*1*311*8*1*37*4*3*41*
Net change in cash(155)*(32)*(45)13*(33)*7*(27)90*66*22*(9)11*

Compare with peers

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
TransMedics Group49119017*34.7M— 10-QJun 30, 2026
Integer Holdings1445037*34.0M— 10-QOct 2, 2026
iRhythm Holdings24722451*33.0M— 10-QJun 30, 2026
Masimo1254044552.4M— 10-QApr 4, 2026
Inspire Medical Systems19120746*29.0M— 10-QSep 30, 2026
Merit Medical Systems50441665*59.9M— 10-QSep 30, 2026
GLAUKOS16221139*59.2M— 10-QSep 30, 2026
Icu Medical29855280*25.0M— 10-QJun 30, 2026
PROCEPT BioRobotics22894(19)*57.3M11.8 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.